HAVCR2 and neoplasm: Recently, focus has shifted towards novel strategies that target LAG3 and TIM3, as well as targeting Tregs and their immunosuppressive factors (e.g. TGF-β) into the tumor microenvironment, which have been proposed as more effective in stimulating an anti-tumor immune response (11).